AUTHORS
Lucrecia Yanez San Segundo, MD, PhD, Pau Abrisqueta, MD, PhD2, Angel Ramirez3, Pablo Mozas, MD, PhD4, Luis Juárez-Salcedo5, Almudena Navarro Bailon6, Izaskun Zeberio, MD7, Adrian Mosquera, MD8, Ana C Oliveira, MD, PhD9, Javier De la Serna, MD, PhD10, Fatima De la Cruz Vicente, MD11, María Terol Castera12, Garcia Malo Maria Dolores13, Marta Crespo, PhD14, Blanca Espinet, MD15, Miguel Alcoceba, PhD16, Alicia Serrano, PhD17, Julio Delgado, MD18, Ana Muntañola Muntanola Prat, MD PhD19, Jose-Angel Hernandez-Rivas, MD, PhD20, Francesc Bosch, MD21
AFFILIATIONS
1 Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, University of Cantabria, Santander, Spain
2 Hospital Vall d´Hebron, Barcelona, Spain
3 Hospital Central de Asturias, Oviedo, Spain
4 Hospital Clinic Barcelona, Barcelona, Spain
5 Hospital de la Princesa, Madrid, Spain
6 Hospital de Salamanca, Salamanca, Spain
7 Hospital de Donosti, San Sebastian, Spain
8 Hospital de Santiago de Compostela, Santiago de Compostela, Spain
9 ICO Bellvitge, Badalona, Spain
10 Hospital 12 de Octubre, Madrid, Spain
11 Hospital Virgen del Rocío, Sevilla, Spain
12 Hospital Clinico de Valencia, Valencia, Spain
13 Hospital Universitario Morales Meseguer, Murcia, Spain
14 VHIO, Barcelona, Spain
15 Hospital del Mar, Barcelona, Spain
16 Hospital de Salamanca, Salamanca, Spain
17 Hospital Clinico de Valencia, Valencia, Spain
18 Hospital Clinic Barcelona, Barcelona, Spain
19 Hospital de Sant Pau, Barcelona, Spain
20 Hospital Infanta Leonor, Madrid, Spain
21 Hospital Vall d´Hebron, Barcelona, Spain
ABSTRACT
Introduction: Transformation to diffuse large B-cell lymphoma (DLBCL-RT) is the most common form of RT and is associated with a dismal prognosis. Although novel therapeutic agents have improved outcomes compared with standard R-CHOP, treatment of RT remains one of the greatest unmet needs in patients with chronic lymphocytic leukemia (CLL). Mosunetuzumab (M), a CD20xCD3 T-cell-engaging bispecific antibody, has shown substantial activity in DLBCL, both as monotherapy and in combination with CHOP.
Here, we report the efficacy and safety results of the pre-specified interim analysis from the Phase 2 GELLC-9-Richter study (NCT06926205), evaluating frontline M-CHOP induction followed by mosunetuzumab monotherapy maintenance in patients (pts) with previously untreated DLBCL-RT.
Methods: Pts received an induction therapy of six cycles, every 21 days, of CHOP combined with IV mosunetuzumab with step-up dosing (1 mg on C1D8, 2 mg on C1D15, and 30 mg on day 1 of cycles 2-6). Responding pts, who were not considered candidates for consolidative allo-SCT or CAR-T, received up to 11 additional cycles of mosunetuzumab maintenance Q3W. The primary endpoint of the study was the rate of metabolic complete response (CR) at the end of induction (EoI), assessed according to the Lugano criteria.
Results: As of the data cut-off (June 1st, 2026), 30 pts (28 with CLL and 2 with SLL) had been enrolled, 28 had received at least one cycle of M-CHOP, 15 pts had completed induction (EoI), and 8 had initiated mosunetuzumab maintenance. The median age was 67 years (range, 50–79), 15 pts were female and ECOG PS was 0-1 in 28 pts (93%). Prior systemic therapy for CLL/SLL had been administered in 15 patients, including 1 prior line in 6 pts (40%) and ≥2 lines in 9 pts (60%); all pts had received at least one targeted therapy. DLBCL-RT was diagnosed from lymph node biopsy in 23 pts and from other tissues in 7 pts. Among the 14 pts evaluated to date, clonal relationship was demonstrated in 12 (86%). At trial inclusion, CLL biological features included unmutated IGHV in 18 pts (60.0%), del(17p) in 12 pts (40%), TP53 mutations in 14 (47%), and a complex karyotype (CK) in 13/28 (46%), including a highly CK (≥5 abnormalities) in 8/13 pts (61%). The median time from CLL/SLL diagnosis to DLBCL-RT was 59.4 months (range, 24.1-156.0), and the median time from DLBCL-RT diagnosis to C1D1 was 21 days (range, 6-43).
Among the 25 pts evaluable at the C4 assessment, the ORR was 80%, including 10 metabolic CRs (40%) and 10 PRs (40%); 2 pts had stable disease (SD), 2 had progressive disease (PD), and 1 died due to cytokine release syndrome (CRS). Among the 18 pts evaluable at EoI (10 pts have not yet reached C7 and 2 did not receive mosunetuzumab due to clinical decision), ORR was 66.7%, with 11 pts (61.1%) achieving a metabolic CR and 1 (5.6%) a PR; 4 pts had PD and 2 died (1 due to PD and 1 due to the previously reported CRS). At the time of analysis, the response of the CLL had also been evaluated by iwCLL criteria in 13 patients, of whom 9 (69.2%) were in CR and 1 (7.7%) in PR. Among the 12 pts in response after EoI, 3 received consolidation with cellular therapy (1 allo-SCT, 2 CAR-T), 1 discontinued therapy due to recurrent infections, and 8 initiated mosunetuzumab maintenance.
In the safety population (n= 30), 26 pts (86.7%) experienced at least one adverse event, 20 (66.7%) experienced a severe adverse event, and 14 (46.7%) experienced an adverse event of special interest. CRS occurred in 10 pts (33.3%), primarily during the step-up dose, and was grade ≤2 in 9/10 cases. No cases of ICANS were reported. Grade 3 and 4 febrile neutropenia occurred in 15 pts (50%) and 1 pt (3.3%), respectively. Six infectious episodes (4 bacteremia, 2 pneumonia) were reported in 4 pts. No fungal infections or viral reactivations were observed.
With a median follow-up of 10.3 months (range 0.9-24.9), the estimated progression free survival and overall survival at 1 year is 86.6% (95% IC, 71.9% - 100%) and 92.8% (95% IC, 83.2% - 100%), respectively.
Conclusions: Frontline M-CHOP achieved high metabolic CR rates and early survival outcomes in pts with untreated DLBCL-RT. The safety profile was consistent with that expected for bispecific antibody-chemotherapy combinations. These findings support M-CHOP as a promising first-line strategy for DLBCL-RT and warrant further evaluation. Updated efficacy and safety will be presented at the meeting.
This clinical trial is supported by Roche
DISCLOSURES
Lucrecia Yanez San Segundo, MD, PhD: JOHNSON&JOHNSON - Honoraria; JOHNSON&JOHNSON - Research Funding; JOHNSON&JOHNSON - Consultancy (Includes expert testimony); ABBVIE - Consultancy (Includes expert testimony)